Straits Times Index
3,298.65 +25.93 (+0.79%) Nikkei
38,329.39 +777.23 (+2.07%) Hang Seng
17,107.38 +278.45 (+1.65%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,594.12 -112.04 (-0.17%) CMC Crypto 200
1,435.68 +20.92 (+1.48%)
SAB Biotherapeutics, Inc. (SABSW)
| Previous close | 0.0300 |
| Open | 0.0300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0300 - 0.0300 |
| 52-week range | 0.0300 - 0.0300 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 0.10 |
| EPS (TTM) | 0.2920 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSAB Biotherapeutics Provides SAB-142 Trial Update
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of ser
- GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at t
- GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 1
